<DOC>
	<DOCNO>NCT00936546</DOCNO>
	<brief_summary>This study evaluate safety efficacy combination rituximab methotrexate treat disable fibrosing skin disorders.Rituximab administer baseline month 6 . The drug consider efficacious skin thickness diminishes substantially .</brief_summary>
	<brief_title>A Protocol Based Treatment Debilitating Fibrosing Skin Disorders With ( Anti-CD 20 ) , Rituximab , Evaluating Safety Efficacy</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Fasciitis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>( Fe ) male &gt; , = 18 year Fibrosing skin disorder , fulfil ACR criterion diffuse SSc Inadequate response methotrexate ( least 12 week 10 mg/w , except tolerate contraindicate Debilitating disease define either one following : Restriction mobility Disfiguration : eg : facial involvement Severe Internal Organ involvement Contraception woman childbearing potential . Sexual abstinence alternative contraception . FVC &lt; , = 50 % LVEF &lt; , = 40 % predict value , DLCO &lt; , = 40 % predict value Exclusion criterion specifically describe protocol antiCD20 : Lack peripheral venous access . Pregnancy breast feeding . Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) . Evidence significant uncontrolled concomitant disease , limited , nervous system , renal , hepatic , endocrine gastrointestinal disorder , investigator 's opinion , would preclude patient participation . Primary secondary immunodeficiency ( history , currently active ) , include know history HIV infection . Known active infection kind ( exclude fungal infection mail bed ) , major episode infection require hospitalization treatment i.v . antiinfectives within 4 week baseline completion oral antiinfectives within 2 week prior baseline . History deep space/tissue infection ( e.g . fasciitis , abscess , osteomyelitis ) within 52 week prior baseline . History serious recurrent chronic infection ( screen chest infection chest radiograph perform screen perform within 12 week prior screen ) . History cancer , include solid tumor , hematologic malignancy carcinoma situ ( except basal cell squamous cell carcinoma skin excise cure ) . History severe allergic anaphylactic reaction biologic agent know hypersensitivity component rituximab murine protein . Concurrent treatment biologic agent DMARD MTX . Treatment must discontinue 14 day prior baseline , except follow : azathioprine ≥ 28 day ; leflunomide ≥ 8 week ( ≥ 14 day 11 day standard cholestyramine activate charcoal washout ) ; infliximab ≥ 8 week ; adalimumab ≥ week . Previous treatment &gt; 1 biological agent . Treatment investigational agent within 28 day baseline 5 halflives investigational drug ( ever longer ) . Receipt vaccine within 28 day prior baseline Intolerance contraindication i.v . glucocorticoid . Positive serum human chorionic gonadotropin ( hCG ) measure screen positive pregnancy test prior first rituximab infusion . Positive test hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) hepatitis C serology . Hemoglobin &lt; 8.0 g/dL . Concentrations serum IgG and/or IgM 5.0 0.40 mg/mL , respectively . Absolute neutrophil count ( ANC ) &lt; 1.5 X 10³/µL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>